{"article": [{"url": "https://www.marketwatch.com/story/sanofi-translate-bio-to-develop-mrna-vaccines-2020-06-23", "published": 1592878760.0, "headline": "Sanofi, Translate Bio to develop mRNA vaccines", "body": "Sanofi SA said Tuesday that it will further its investment in U.S.-based Translate Bio Inc. to pursue new mRNA vaccines aimed at broadly addressing infectious diseases. Translate Bio will receive $425 million in upfront payments, consisting of a $300 million cash payment and a $125 million investment in private placement common stock at $25.59 a share. Translate Bio is also eligible for other payments up to $1.9 billion. Sanofi will receive world-wide rights to develop and commercialize infectious disease vaccines using Translate Bio's technology, the French pharmaceutical company said. Both companies are currently evaluating multiple coronavirus vaccine candidates and the companies have the goal of initiating a first-in-human clinical trial in the fourth quarter of 2020. Write to Jessica Sier at jessica.sier@wsj.com"}]}